Multiple Myeloma (Kahler's Disease) – Pipeline Review, H1 2012

Multiple Myeloma (Kahler's Disease) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2012', provides an overview of the Multiple Myeloma (Kahler's Disease) therapeutic pipeline. This report provides information on the therapeutic development for Multiple Myeloma (Kahler's Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler's Disease). 'Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Multiple Myeloma (Kahler's Disease).
• A review of the Multiple Myeloma (Kahler's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Multiple Myeloma (Kahler's Disease) pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler's Disease).
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler's Disease) pipeline depth and focus of Multiple Myeloma (Kahler's Disease) therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Multiple Myeloma (Kahler's Disease) Overview
Therapeutics Development
An Overview of Pipeline Products for Multiple Myeloma (Kahler's Disease)
Multiple Myeloma (Kahler's Disease) Therapeutics under Development by Companies
Multiple Myeloma (Kahler's Disease) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Multiple Myeloma (Kahler's Disease) Therapeutics – Products under Development by Companies
Multiple Myeloma (Kahler's Disease) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Multiple Myeloma (Kahler's Disease) Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Kyowa Hakko Kirin Co., Ltd.
Abbott Laboratories
Eli Lilly and Company
Viralytics Ltd.
GlaxoSmithKline plc
Seattle Genetics, Inc.
Genentech, Inc.
Gilead Sciences, Inc.
Biotest AG
Merck & Co., Inc.
Micromet, Inc.
Takeda Pharmaceutical Company Limited
BioSante Pharmaceuticals, Inc.
ZIOPHARM Oncology, Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Cephalon, Inc.
Human Genome Sciences, Inc.
ImmunoGen, Inc.
Pfizer Inc.
Sunesis Pharmaceuticals, Inc.
SuperGen, Inc.
Genmab A/S
Cyclacel Pharmaceuticals Inc.
Celgene Corporation
Onyx Pharmaceuticals, Inc.
Incyte Corporation
Geron Corporation
MannKind Corporation
Merck KGaA
4SC AG
EntreMed, Inc.
Innate Pharma SA
Piramal Life Sciences Limited
SymBio Pharmaceuticals Limited
Chroma Therapeutics Ltd.
Avaris
Abiogen Pharma S.p.A.
Acceleron Pharma, Inc.
Aquinox Pharmaceuticals Inc.
Coronado Biosciences, Inc.
Arno Therapeutics, Inc.
Vaccinex, Inc.
CanBas Co., Ltd.
NovImmune SA
Axelar AB
Immune System Therapeutics Ltd.
Concert Pharmaceuticals, Inc.
NOXXON Pharma AG
Xencor, Inc.
Acetylon Pharmaceuticals, Inc.
Tragara Pharmaceuticals, Inc.
PharmaMar, S.A.
AB Science
Biokine Therapeutics Ltd.
Cylene Pharmaceuticals, Inc.
Nereus Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc.
EUSA Pharma, Inc.
TAU Therapeutics, LLC
Immunovative Therapies, Ltd.
Multiple Myeloma (Kahler's Disease) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Perifosine - Drug Profile
LBH589 - Drug Profile
Carfilzomib - Drug Profile
Elotuzumab - Drug Profile
Aplidin - Drug Profile
Velcade + Cyclophosphamide + Dexamethasone - Drug Profile
Zolinza - Drug Profile
Velcade + Thalidomide + Dexamethasone - Drug Profile
Velcade + Dexamethasone - Drug Profile
Aplidin + Dexamethasone - Drug Profile
LBH589 + Bortezomib + Dexamethasone - Drug Profile
Revlimid + Dexamethasone - Drug Profile
Actimid + Dexamethasone - Drug Profile
Carfilzomib + Revlimid + Dexamethasone - Drug Profile
Actimid - Drug Profile
Tanespimycin + Velcade - Drug Profile
Melphalan + Prednisolone + Thalidomide - Drug Profile
Perifosine + Velcade + Dexamethasone - Drug Profile
Zolinza + Bortezomib - Drug Profile
LBH589 + Bortezomib - Drug Profile
Revlimid + Melphalan + Prednisone - Drug Profile
HuLuc63 + Lenalidomide + Dexamethasone - Drug Profile
Prednisolone - Drug Profile
Masitinib + Velcade + Dexamethasone - Drug Profile
Multiple Myeloma (Kahler's Disease) Therapeutics – Drug Profile Updates
Multiple Myeloma (Kahler's Disease) Therapeutics – Discontinued Products
Multiple Myeloma (Kahler's Disease) Therapeutics - Dormant Products
Multiple Myeloma (Kahler's Disease) – Product Development Milestones
Featured News & Press Releases
Jan 06, 2012: Immune System Therapeutics Announce Recruitment Of Patients With Kappa-Type Myeloma In Phase II Trial Of MDX-1097
Dec 26, 2011: SymBio Initiates Phase II Trial Of Bendamustine HCl In Multiple Myeloma In Japan
Dec 19, 2011: Patrys Provides Update On Upcoming Clinical Trial Program In Multiple Myeloma Patients
Dec 13, 2011: Presentations Highlight Results Of Studies With MLN9708, First Oral Proteasome Inhibitor In Early Stage Clinical Trials In Multiple Myeloma
Dec 13, 2011: Phase III Study Evaluating REVLIMID In Patients With High-Risk Smoldering Multiple Myeloma Presented At ASH
Dec 12, 2011: Celgene Announces Phase II Study Evaluates Clinical Benefit Of Pomalidomide In Heavily Pre-treated Patients With Multiple Myeloma
Dec 12, 2011: Acetylon Announces Publication Of Preclinical Pharmacokinetic, Pharmacodynamic And Bone Disease Results for ACY-1215 in Multiple Myeloma
Dec 12, 2011: BioInvent Presents New Preclinical Data Of BI-505 At American Society Of Hematology Annual Meeting
Dec 12, 2011: Biotest’s Clinical Development Of BT-062 In Multiple Myeloma Expands Into Combination Therapy
Dec 12, 2011: Phase III Study With REVLIMID Continuous Therapy Demonstrates Statistically Significant Improvement In Progression-Free Survival For Patients Newly Diagnosed With Multiple Myeloma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Multiple Myeloma (Kahler's Disease), H1 2012
Products under Development for Multiple Myeloma (Kahler's Disease) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Bristol-Myers Squibb Company, H1 2012
Johnson & Johnson, H1 2012
Kyowa Hakko Kirin Co., Ltd., H1 2012
Abbott Laboratories, H1 2012
Eli Lilly and Company, H1 2012
Viralytics Ltd., H1 2012
GlaxoSmithKline plc, H1 2012
Seattle Genetics, Inc., H1 2012
Genentech, Inc., H1 2012
Gilead Sciences, Inc., H1 2012
Biotest AG, H1 2012
Merck & Co., Inc., H1 2012
Micromet, Inc., H1 2012
Takeda Pharmaceutical Company Limited, H1 2012
BioSante Pharmaceuticals, Inc., H1 2012
ZIOPHARM Oncology, Inc., H1 2012
Millennium Pharmaceuticals, Inc., H1 2012
Novartis AG, H1 2012
Cephalon, Inc., H1 2012
Human Genome Sciences, Inc., H1 2012
ImmunoGen, Inc., H1 2012
Pfizer Inc., H1 2012
Sunesis Pharmaceuticals, Inc., H1 2012
SuperGen, Inc., H1 2012
Genmab A/S, H1 2012
Cyclacel Pharmaceuticals Inc., H1 2012
Celgene Corporation, H1 2012
Onyx Pharmaceuticals, Inc., H1 2012
Incyte Corporation, H1 2012
Geron Corporation, H1 2012
MannKind Corporation, H1 2012
Merck KGaA, H1 2012
4SC AG, H1 2012
EntreMed, Inc., H1 2012
GENTIUM S.p.A., H1 2012
Celldex Therapeutics, Inc., H1 2012
AEterna Zentaris Inc., H1 2012
ImmunoCellular Therapeutics, Ltd., H1 2012
IMMUNOMEDICS, INC, H1 2012
Ligand Pharmaceuticals Incorporated, H1 2012
Avalon Pharmaceuticals, Inc., H1 2012
Cleveland BioLabs, Inc., H1 2012
Oncolytics Biotech Inc., H1 2012
Compugen Ltd., H1 2012
Patrys Limited, H1 2012
Curis, Inc., H1 2012
Keryx Biopharmaceuticals, Inc., H1 2012
Alexion Pharmaceuticals, Inc., H1 2012
Telik, Inc., H1 2012
CytRx Corporation, H1 2012
Pharmacyclics, Inc., H1 2012
Array BioPharma Inc., H1 2012
MorphoSys AG, H1 2012
BioInvent International AB, H1 2012
Senesco Technologies, Inc., H1 2012
Choongwae Pharma Corp, H1 2012
Quest PharmaTech Inc., H1 2012
Threshold Pharmaceuticals, Inc., H1 2012
CrystalGenomics, Inc., H1 2012
Innate Pharma SA, H1 2012
Piramal Life Sciences Limited, H1 2012
SymBio Pharmaceuticals Limited, H1 2012
Chroma Therapeutics Ltd., H1 2012
Avaris, H1 2012
Abiogen Pharma S.p.A., H1 2012
Acceleron Pharma, Inc., H1 2012
Aquinox Pharmaceuticals Inc., H1 2012
Coronado Biosciences, Inc., H1 2012
Arno Therapeutics, Inc., H1 2012
Vaccinex, Inc., H1 2012
CanBas Co., Ltd., H1 2012
NovImmune SA, H1 2012
Axelar AB, H1 2012
Immune System Therapeutics Ltd., H1 2012
Concert Pharmaceuticals, Inc., H1 2012
NOXXON Pharma AG, H1 2012
Xencor, Inc., H1 2012
Acetylon Pharmaceuticals, Inc., H1 2012
Tragara Pharmaceuticals, Inc., H1 2012
PharmaMar, S.A., H1 2012
AB Science, H1 2012
Biokine Therapeutics Ltd., H1 2012
Cylene Pharmaceuticals, Inc., H1 2012
Nereus Pharmaceuticals, Inc., H1 2012
AVEO Pharmaceuticals, Inc., H1 2012
EUSA Pharma, Inc., H1 2012
TAU Therapeutics, LLC, H1 2012
Immunovative Therapies, Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Multiple Myeloma (Kahler's Disease) Therapeutics – Drug Profile Updates
Multiple Myeloma (Kahler's Disease) Therapeutics – Discontinued Products
Multiple Myeloma (Kahler's Disease) Therapeutics – Dormant Products

LIST OF FIGURES

Number of Products under Development for Multiple Myeloma (Kahler's Disease), H1 2012
Products under Development for Multiple Myeloma (Kahler's Disease) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012 Skip to top